In a deal that Aspect Biosystems Ltd. CEO Tamer Mohamed suggested could mean science fiction coming to real life, the Vancouver, BC-based firm focused on bioprinted tissue therapeutics is teaming with Novo Nordisk A/S to develop allogeneic cell therapies for type 1 diabetes. The companies unveiled their partnership on 12 April, with Aspect getting $75m up front plus up to $650m in earnouts tied to as many as four programs.
A leader in the diabetes space, Novo Nordisk has been working on stem-cell-derived islet cell therapies for type 1 diabetes for years and told Scrip it sees Aspect’s technology, which offers immune-resistant encapsulation for cell therapies, as potentially a safe way to deliver such therapies to patients. Spun out from technology developed at the University of British Columbia, Aspect inked a partnership with Johnson & Johnson affiliate DePuy Synthes in 2017 to develop a bioprinted tissue device for surgical knee meniscus replacement
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
